Log In
Print this Print this


Also known as: ISV-401

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
Description1% azithromycin with InSite's DuraSite ophthalmic drug delivery system
Molecular Target Ribosomal 50S subunit
Mechanism of ActionProkaryotic protein synthesis inhibitor
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentMarketed
Standard IndicationConjunctivitis
Indication DetailsTreat acute bacterial conjunctivitis; Treat bacterial conjunctivitis
Regulatory Designation
PartnerAkorn Inc.;
Pfizer Inc.;
Senju Pharmaceutical Co. Ltd.;
VISUfarma B.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today